A Comparative, Randomized, Single-Dose, 2-Way Crossover Pharmacokinetic Comparability Study of CB-839 Administered as Capsule and Tablet Formulations in Healthy Adult Subjects

Trial Profile

A Comparative, Randomized, Single-Dose, 2-Way Crossover Pharmacokinetic Comparability Study of CB-839 Administered as Capsule and Tablet Formulations in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs CB 839 (Primary) ; CB 839 (Primary)
  • Indications Haematological malignancies; Leukaemia; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 03 Jan 2017 Status changed from not yet recruiting to completed.
    • 27 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top